Open an account

Defiance Daily Target 2X Long DRAM ETF

DRAL · ETF

$6.72+$0.36 (+5.66%)TodayMarket closed ·
Prev close $6.36

About DRAL

DRAL was created on 2026-06-24 by Defiance. The fund's investment portfolio concentrates primarily on information technology equity. DRAL seeks to deliver 2x leveraged exposure to the daily share price movements of the Roundhill Memory ETF (DRAM), less fees and expenses, through derivatives such as options and swap agreements.

Issuer
Defiance
Expense ratio
0.71%
Assets under management
$12.73M
Inception
Jun 24, 2026
Asset class
Equity
Website
defianceetfs.com

DRAL key statistics

Price-earnings ratio
0.00
Average volume
170.91K
Volume
101.49K
Open price
$6.62
High today
$6.91
Low today
$6.58
52 Week high
$25.52
52 Week low
$6.25

Defiance Daily Target 2X Long DRAM ETF (DRAL) at a glance

Defiance Daily Target 2X Long DRAM ETF (DRAL) last traded at $6.72, with a price-to-earnings ratio of 0.00.

Today the fund has traded between $6.58 and $6.91. The current price is 2.1% above the day's low and 2.7% below its high.

Volume so far is 101.49K shares, below the average of 170.91K shares a day.

Over the past year Defiance Daily Target 2X Long DRAM ETF has ranged from $6.25 to $25.52, and now sits 2% of the way up that range.

DRAL news

  • Chandrima Sanyal

    AI Mania Pushes Leveraged ETFs to New Highs as US Market Nears 700 Funds: What Investors Need to Know

  • Chandrima Sanyal

    The AI Memory Trade Is Heating Up: Defiance Launches 2X DRAM ETF After Micron's Blowout Quarter

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.